Physician profile
Thomas P Arnold
NPI 1215923859
$82,455.66
in general payments reported to CMS, 2019-2025
14 companies · $94.28 in 2025
The $94.28 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,496 · 2020: $3,239 · 2021: $22K · 2022: $52K · 2023: $369 · 2024: $196 · 2025: $94.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $47,625.91 | 2020-2023 | Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26,538.50 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $6,158.03 | 2022-2024 | Alden Scleral Zenlens, Xiidra |
| Novartis Pharmaceuticals Corporation | $593.14 | 2019-2021 | |
| Visioneering Technologies, INC. | $528.61 | 2019-2021 | |
| Glaukos Corporation | $331.80 | 2023 | Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Sun Pharmaceutical Industries INC. | $204.30 | 2019-2024 | |
| Alcon Vision LLC | $151.78 | 2019-2025 | Precision7 |
| Abbvie INC. | $116.34 | 2022 | |
| Optos, INC. | $98.47 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $50.27 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $23.90 | 2021 | |
| Shire North American Group INC | $23.07 | 2019 | |
| Abb Con-Cise Optical Group LLC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.